CONFERENCE DAY two
SEPTEMBER 10, 2024
SHOWCASE YOUR SCIENCE CONTINUED
7:40 am Chair’s Opening Remarks
7:45 am The ADC Dream: Why ADCs are More Alive Than Ever
Synopsis
- Answering the question, what is the dream for ADCs?
- Evaluating and learning from the journey for ADCs to hit their stride
- Outlining why ADCs are now seeing success and what the future holds
WHAT’S THE NEXT PAYLOAD? DEVELOPING A DIFFERENTIATED ADC FOR FUTURE FIRST-IN-LINE THERAPEUTIC OPTIONS
8:15 am Panel Discussion: DACs, Protacs & Molecular Glues: Why is ADC Technology What Protein Degradation Needs?
Synopsis
- Discussing mechanistic differences across protein degradation payloads, their therapeutic role, and liabilities
- Demonstrating a protein degradation therapeutic window, and selective delivery with antibodies
- Understanding why protein degradation experts believe ADC technology is needed
8:45 am TPD²: Cell Selective Degradation
Synopsis
- Improving upon efficacy, safety, and half-life of conventional targeted protein degraders
- Orum’s proprietary Dual-precision Targeted Protein Degradation (TPD² ™) approach uses antibodies to precisely deliver small molecule targeted protein degrader payloads to cancer cells
- Discussing collaboration possibilities across TPD² and TPS² platforms and programs
9:05 am Degrader Antibody Conjugates
Synopsis
- Degrader Antibody Conjugates (DACs) combine the unique strengths of ADCs with selective protein degraders
- A platform to deliver high quality conjugates with diverse degrader chemical matter
- DACs are efficacious in vivo across a wide variety of tumor types
9:25 am Morning Break & Networking
10:00 am Tumor-Specific Delivery of Potent Degraders
Synopsis
- Introducing Nurix’ expertise in DELigase, targeted protein modulation, targeted protein degradation, targeted protein elevation, and degrader-antibody conjugates
- Targeting degraders to the CNS for the treatment of cancer
- Discussing collaborations
REVISITING & DISCOVERING NEW TARGET OPPORTUNITIES TO EXPAND ADC & RADIOLIGAND DELIVERY
10:20 am Development of a Priming Approach to Enhance Antigen-directed Therapies in Hematological Malignancies & Solid Tumors
Synopsis
- Session details to be released
10:40 am Mbrace Therapeutics: Developing Novel Targets & Antibodies using SPARTA
Synopsis
- SPARTA is a phage-based library of human antibodies
- This antibody library can be used for discovery of new antibody/target pairs
- SPARTA
11:00 am Roundtable Discussions for Scientific Alignment:
Synopsis
Join roundtables of companies across novel linker and conjugation technologies, future payloads, and radioligands; or
groups identifying new targets in expanded tumor types, to discuss how exciting new science can revolutionize existing or open up new targets.
CHEMISTRY TABLE
Can we Succeed by Applying New Technology to Known Targets?
Debating the notion of known ADC targets seeing a change in success with the new linker payload format
Discussing the industry’s sentiment on a second look, with more stable conjugation and release chemistry
that takes advantage of different enzymes and payloads
Judging the potential therapeutic window of phase 1 by
comparing preclinical data of new and historical studies
BIOLOGY TABLE
How Do You Make a “Cold Tumor”, Hot?
Comparing hot and cold tumors in the context of ADCs, including known examples to evaluate the most promising market opportunities for ADC
Discussing factors of a tumor that lead to response as hot versus cold to further the field’s understanding
Evaluating opportunity and means to turn a cold tumor hot, to improve response to ADCs, including immunebased combination therapy
11:30 am Session Reserved for PINOTBIO
11:50 am Session Reserved for Shanghai Escugen Biotechnology
12:10 pm Lunch & Networking
CREATIVE PARTNERSHIPS & DEAL PROCESSES: HOW TO DIFFERENTIATE IN THE BUY/SELL DYNAMIC
1:20 pm Therapeutic Index Improvements of ADCs: What Are the Next Breakthroughs?
Synopsis
- Discussing the impact of ADC design on anti-tumor activity and platform adverse events
- Clinical liabilities of Exatecan/Top1 based ADCs and mitigation strategies
- Dual payload conjugates: same or better than chemo combos?
1:40 pm Effectively & Efficiently Structuring Deal Processes as a Small ADC or Radiopharmaceutical Company
Synopsis
- Discussing the panel’s experiences executing and performing due diligence for noteworthy ADC and radiopharma, mergers, and licensing deals
- Sharing pharma’s expectation for data packages and deal process; how to differentiate in the buy/sell dynamic
- Outlining creative partnerships and deal structures that create effective BD&L in 2024
2:00 pm Afternoon Break & Networking
2:30 pm Adding Value to US Pipelines Through Asian Assets & Fast-Tracking US Innovation Through Efficiency in China
Synopsis
- Discussing deals with Asia to date, their characteristics, and the change in momentum
- Highlighting the benefits of US phase 1 trials of Asian assets to overcome the challenge of underreporting of patient reported toxicity and leveraging efficiency in China to fast-track US innovation through clinical studies
- Reviewing increasing US ADC portfolios more cost-effectively through phase 1 Asian assets
3:00 pm MediLink Corporate Presentation
Synopsis
- Company Overview
- TMALIN® ADC Platform Introduction
- Partnering Strategy